[Ten year's experience with combined hepatitis A and B vaccine]

Hepatitis A and B are still a serious global public health problem. Monovalent vaccines against hepatitis A and B have been available on the European but also on the Czech market for long time. Since 1997 different formulations and immunization schedules of the first combined vaccine against both diseases have been gradually introduced into clinical practice. Twinrix Adult (with conventional and accelerated schedules), and Twinrix Paediatric are available for all patients in Europe and also in USA. AmBirix as a two scheduled vaccine for age from 1-15years is licensed in Europe. These vaccines offer fewer injections for satisfactory protection against hepatitis A and B and an excellent safety and reactogenicity profile in comparison to monovalent vaccines. This review is dominantly focused on immunogenicity, safety and reactogenicity data of the vaccine, which are available now for more than 10 years.